ACADIA announces advancement by Allergan of novel glaucoma compound

ACADIA Pharmaceuticals (ACAD) announced that Allergan (AGN) has advanced an additional product candidate as a potential new treatment for glaucoma. Allergan is responsible for development and has worldwide rights to commercialize products advanced under the companies’ glaucoma collaboration. ACADIA is eligible to receive payments upon the successful achievement of clinical and regulatory milestones as well as royalties on future worldwide product sales, if any, the company said.

View Comments (0)